Glioma growth inhibition by neurostatin and O-But GD1b

Neuro-Oncology

Volumn 12, Issue 11, 2010, Pages 1135-1146

  Valle Argos, Beatriz ^a   Gómez Nicola, Diego ^a,b   Nieto Sampedro, Manuel ^a,b  

^a INSTITUTO CAJAL   (Spain)

^b HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

Author keywords

C6 cells; Gangliosides; Glioma; Neurostatin; O But GD1b

Indexed keywords

GANGLIOSIDE; GANGLIOSIDE GD 1B; NEUROSTATIN; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BUTYRYLATION; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG STABILITY; FEMALE; GLIOMA; IMMUNE RESPONSE; MACROPHAGE; MALE; MOUSE; NONHUMAN; RAT; T LYMPHOCYTE; TUMOR XENOGRAFT;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; FLOW CYTOMETRY; GANGLIOSIDES; GLIOMA; GLYCOSPHINGOLIPIDS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; RATS; RATS, SPRAGUE-DAWLEY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650088628     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq073     Document Type: Article

References (41)

1. Kanu OO, Mehta A, Di C, et al. Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets. 2009;13:701-718.
2. Friedman H. What is "hope" for a patient with a deadly brain tumor? Cerebrum: The DANA Forum on Brain Science. 2003;5:7-18.
3. Klenk E. Über die ganglioside, eine neue gruppe von zucherhaltigen gehirnlipoiden. Hoppe Seylers Z Physiol Chem. 1942;273:76-86.
4. Yamashita T, Wada R, Sasaki T, et al. A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci USA. 1999;96:9142-9147.
5. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996;56:5309-5318.
6. Miljan EA, Bremer EG. Regulation of growth factor receptors by gangliosides. Sci STKE. 2002;2002:RE15.
7. Seyfried TN, Yu RK, Saito M, Albert M. Ganglioside composition of an experimental mouse brain tumor. Cancer Res. 1987;47:3538-3542.
8. Wagener R, Rohn G, Schillinger G, Schroder R, Kobbe B, Ernestus RI. Ganglioside profiles in human gliomas: quantification by microbore high performance liquid chromatography and correlation to histomorphology and grading. Acta Neurochir (Wien). 1999;141:1339-1345.
9. Comas TC, Tai T, Kimmel D, et al. Immunohistochemical staining for ganglioside GD1b as a diagnostic and prognostic marker for primary human brain tumors. Neurooncology. 1999;1:261-267.
10. Sung CC, Pearl DK, Coons SW, et al. Correlation of ganglioside patterns of primary brain tumors with survival. Cancer. 1995;75:851-859.
11. Furuhata K. Chemistry of N-acetylneuraminic acid (Neu5Ac). Trends Glycosci Glycotech. 2004;16:146-169.
12. Varki A. Diversity in the sialic acids. Glycobiology. 1992;2:25-40.
13. Abad-Rodriguez J, Vallejo-Cremades M, Nieto-Sampedro M. Control of glial number: purification from mammalian brain extracts of an inhibitor of astrocyte division. Glia. 1998;23:156-168.
14. Abad-Rodriguez J, Bernabe M, Romero-Ramirez L, Vallejo-Cremades M, Fernandez-Mayoralas A, Nieto-Sampedro M. Purification and structure of neurostatin, an inhibitor of astrocyte division of mammalian brain. J Neurochem. 2000;74:2547-2556.
15. Nieto-Sampedro M, Bailon C, Fernandez-Mayoralas A, Martin-Lomas M, Mellstrom B, Naranjo JR. Experimental brain glioma: growth arrest and destruction by a blood-group-related tetrasaccharide. J Neuropathol Exp Neurol. 1996;55:169-177.
16. Valle-Argos B, Gomez-Nicola D, Nieto-Sampedro M. Chemical synthesis of glycolipid derivatives with high inhibitory activity of glioma tumor growth: in-vitro and in-vivo approaches. Neurooncology. 2008;10:1148.
17. McCarthy KD, de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol. 1980;85:890-902.
18. Gomez-Nicola D, Valle-Argos B, Pita-Thomas DW, Nieto-Sampedro M. Interleukin 15 expression in the CNS: blockade of its activity prevents glial activation after an inflammatory injury. Glia. 2008;56:494-505.
19. Smith GM, Rutishauser U, Silver J, Miller RH. Maturation of astrocytes in vitro alters the extent and molecular basis of neurite outgrowth. Dev Biol. 1990;138:377-390.
20. Valle-Argos B, Gomez-Nicola D, Nieto-Sampedro M. Synthesis and characterization of neurostatin-related compounds with high inhibitory activity of glioma growth. Eur J Med Chem. 2010;45:2034-2043.
21. Gomez-Nicola D, Valle-Argos B, Suardiaz M, Taylor JS, Nieto-Sampedro M. Role of IL-15 in spinal cord and sciatic nerve after chronic constriction injury: regulation of macrophage and T-cell infiltration. J Neurochem. 2008;107:1741-1752.
22. Ogura H, Furuhata K, Sato S, Anazawa K, Itoh M, Shitori Y. Synthesis of 9-O-acyl- and 4-O-acetyl-sialic acids. Carbohydr Res. 1987;167: 77-86.
23. Hubl U, Ishida H, Kiso M, Hasegawa A, Schauer R. Studies on the specificity and sensitivity of the influenza C virus binding assay for 9-O-acetylated sialic acids and its application to human melanomas. J Biochem. 2000;127:1021-1031.
24. Williams MA, McCluer RH. The use of Sep-Pak C18 cartridges during the isolation of gangliosides. J Neurochem. 1980;35:266-269.
25. Gomez-Nicola D, Doncel-Perez E, Nieto-Sampedro M. Regulation by GD3 of the proinflammatory response of microglia mediated by interleukin-15. J Neurosci Res. 2006;83:754-762.
26. Rasband WS. ImageJ 1.38x. 1997-2008: ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA. http://rsb.info.nih. gov/ij/,1997-2007.
27. Nieto-Sampedro M. Astrocyte mitogen inhibitor related to epidermal growth factor receptor. Science. 1988;240:1784-1786.
28. Nieto-Sampedro M, Broderick JT. A soluble brain molecule related to epidermal growth factor receptor is a mitogen inhibitor for astrocytes. J Neurosci Res. 1989;22:28-35.
29. Romero-Ramirez L, Nieto-Sampedro M. Inhibiting human astrocytoma growth: structure-activity relationships in neurostatin related glycolipids. J Med Chem. 2004;47:4983-4984.
30. Santos-Benito FF, Fernandez-Mayoralas A, Martin-Lomas M, Nieto-Sampedro M. Inhibition of proliferation of normal and transformed neural cells by blood group-related oligosaccharides. J Exp Med. 1992;176:915-918.
31. El-Rayes BF, LoRusso PM. Targeting the epidermal growth factor receptor. Br J Cancer. 2004;91:418-424.
32. Karpel-Massler G, Schmidt U, Unterberg A, Halatsch ME. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand? Mol Cancer Res. 2009;7:1000-1012.
33. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med. 1983;1:511-529.
34. Miljan EA, Meuillet EJ, Mania-Farnell B, et al. Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides. J Biol Chem. 2002;277:10108-10113.
35. Van Brocklyn J, Bremer EG, Yates AJ. Gangliosides inhibit platelet-derived growth factor-stimulated receptor dimerization in human glioma U-1242MG and Swiss 3T3 cells. J Neurochem. 1993;61:371-374.
36. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211-225.
37. Fathallah-Shaykh HM, Gao W, Cho M, Herrera MA. Priming in the brain, an immunologically privileged organ, elicits anti-tumor immunity. Int J Cancer. 1998;75:266-276.
38. Holladay FP, Choudhuri R, Heitz T, Wood GW. Generation of cytotoxic immune responses during the progression of a rat glioma. J Neurosurg. 1994;80:90-96.
39. Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol. 1996;105: 344-352.
40. Calzascia T, Di Berardino-Besson W, Wilmotte R, et al. Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumorspecific CTL to the brain. J Immunol. 2003;171:2187-2191.
41. Gomez-Nicola D, Valle-Argos B, Nieto-Sampedro M. Blockade of IL-15 activity inhibits microglial activation through the NFkB, p38 and ERK1/2 pathways, reducing cytokine and chemokine release. Glia. 2009;58:264-276.